| DC65452 |
Oleoyl-L-alpha-lysophosphatidic acid sodium salt
Featured
|
Oleoyl-L-alpha-lysophosphatidic acid sodium salt is an essential metabolite for membrane biosynthesis. LPA interacts with the G protein-coupled receptors (GPCRs), called the LPA receptor and mediates signaling. It acts as a endogenous agonist for LPA1 and LPA2 receptors. |
|
| DC65453 |
Norepinephrine tartrate
Featured
|
Norepinephrine tartrate is a potent agonist of adrenergic receptor (AR). Norepinephrine activates α1, α2, β1 receptors. |
|
| DC65454 |
Indusatumab Vedotin
Featured
|
Indusatumab vedotin (MLN-0264) is an antibody-drug conjugate (ADC) composed of an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody and a anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE). |
|
| DC65455 |
Telisotuzumab vedotin
Featured
|
Telisotuzumab vedotin (Teliso-V, ABBV-399) is an antibody-drug conjugate (ADC) composed of the anti–c-Met humanized monoclonal antibody coupled to the cytotoxic monomethyl auristatin E (MMAE) through a mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used for research on advanced solid tumours. |
|
| DC65456 |
Trastuzumab duocarmazine
Featured
|
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas[1]. |
|
| DC65457 |
Trastuzumab MMAE
Featured
|
Trastuzumab MMAE is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody, conjugated to Monomethyl Auristatin E (MMAE), via a Mc linker. Trastuzumab MMAE has the potential for use in research of solid tumors mainly in HER2-positive breast cancer. |
|
| DC65458 |
Denintuzumab mafodotin
Featured
|
Depatuxizumab Mafodotin (Depatux-M, ABT-414) is an antibody-drug conjugate consisting of an EGFR IGg1 monoclonal antibody conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link. Depatuxizumab Mafodotin is used in the treatment of recurrent EGFR-amplified Glioblastoma (GBM). |
|
| DC65459 |
Enapotamab vedotin
Featured
|
Enapotamab vedotin (EnaV, HuMAX-AXL-ADC) is an AXL-specific human IgG1 antibody conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE) through a protease cleavable valine-citrulline (vc) linker. |
|
| DC65460 |
Zilovertamab vedotin
Featured
|
Zilovertamab vedotin (VLS-101, MK-2140) is an antibody-drug conjugate (ADC) composed of a humanised monoclonal antibody targeting ROR1 and the anti-mitotic cytotoxic agent monomethyl auristatin E (MMAE). It has potential for the treatment of lymphoid malignancies. |
|
| A274 |
Patritumab deruxtecan
Featured
|
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity[1]. |
|
| DC65462 |
Cantuzumab mertansine
Featured
|
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts[1][2]. |
|
| DC65463 |
Clivatuzumab-MMAE
Featured
|
Clivatuzumab-MMAE is an antibody-drug conjugate (ADC) composed of a humanized anti-mucin (MUC1) monoclonal antibody and a anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). |
|
| DC65464 |
Farletuzumab-MMAE
Featured
|
Farletuzumab-MMAE is an antibody-drug conjugate (ADC) composed of humanized anti-human folate receptor-alpha (FRα) and the cytotoxic agent monomethyl auristatin (MMAE) via a MC-Vc linker. It has a potent antitumor activity. |
|
| DC65465 |
L-Ascorbic Acid Phospate Magnesium Salt Hydrate
Featured
|
L-ascorbic acid 2-phosphate (2-Phospho-L-ascorbic acid) magnesium hydrate is a long-acting vitamin C derivative that can stimulate collagen formation and expression. L-ascorbic acid 2-phosphate magnesium hydrate can be used as a culture medium supplement for the osteogenic differentiation of human adipose stem cells (hASCs). L-ascorbic acid 2-phosphate magnesium hydrate increases alkaline phosphatase (ALP) activity and expression of runx2A in hASCs during the osteogenic differentiation[1][2][3]. |
|
| DC65466 |
Phenylthiourea
Featured
|
1-PHENYL-2-THIOUREA(N-Phenylthiourea, PTU, Phenylthiocarbamide) is an inhibitor of tyrosinase (Tyr). 1-PHENYL-2-THIOUREA blocks pigmentation and improves optical transparency in zebrafish (Danio rerio) embryo. |
|
| DC65467 |
Kojic acid dipalmitate
Featured
|
Kojic acid dipalmitate (Kojic dipalmitate) is a derivative of Kojic acid (HY-W050154), a fungal metabolite that can be produced by species of Aspergillus, Acetobacter and Penicillium. Kojic acid dipalmitate is a slow and reversible competitive inhibitor of tyrosinase. Kojic acid dipalmitate can be used for skin‐lightening agent research[1]. |
|
| DC65468 |
Influenza Hemagglutinin (HA) Peptide
Featured
|
HA Peptide (HA tag) is a nine amino acids peptide derived from the human influenza hemagglutinin (HA). It is extensively used to isolate, purify, detect, and track the protein of interest in cell biology and biochemistry. |
|
| DC65469 |
Penicillin, streptomycin
Featured
|
Penicillin-Streptomycin is used to prevent microbial contamination of cell culture during long-term in vitro cell culture maintenance. |
.png)
|
| DC65470 |
Belantamab Mafodotin
Featured
|
Belantamab mafodotin (GSK2857916) is a humanized, afucosylated, anti-B-cell maturation antigen (BCMA) monoclonal antibody-drug conjugate (ADC) conjugated to MMAF (HY-15579) via a maleimidocaproyl linker (McMMAF, HY-15578). Belantamab mafodotin shows anti-myeloma activity[1][2]. |
|
| A152 |
Codrituzumab-MMAE Biosimilar(Anti-GPC3 / Glypican-3 Reference Antibody)
Featured
|
Codrituzumab-MMAE, is an antibody-drug conjugate composed of a anti-GPC3 monoclonal antibody and a cytotoxic tubulin polymerase inhibitor conjugated through MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) type linker. |
|
| DC65472 |
Pifithrin-β
Featured
|
Pifithrin-β (PFT β hydrobromide; Cyclic Pifithrin-α hydrobromide) is a potent inhibitor of p53 with an IC50 of 23 μM and is regarded as a lead compound for cancer and neurodegenerative disease therapy. |
|
| DC65473 |
Mps1-IN-6
Featured
|
Mps1-IN-6 is a potent Mps1 inhibitor with an IC50 value of 2.596 nM. Mps1-IN-6 shows antiproliferative activity. Mps1-IN-6 shows antitumor activity. |
|
| DC65474 |
TMRE
Featured
|
TMRE is a mitochondria specific dye (λex=550 nm, λem=575 nm). |
|
| DC65475 |
JKE-1674
Featured
|
JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor. JKE-1674 kills cells in a manner that is equipotent to ML210 and is completely rescued by ferroptosis inhibitors[1]. |
|
| DC65476 |
Serclutamab talirine
Featured
|
Serclutamab Talirine (ABBV-321), is an antibody-drug conjugate (ADC) composed of an humanized immunoglobulin G1 anti-EGFR monoclonal antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer via a maleimidocaproyl-valine-alanine linker. Serclutamab Talirine has the potential for use in advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR) or its ligands. |
|
| DC65477 |
Laprituximab emtansine
Featured
|
Laprituximab emtansine (IMGN-289) is an immunotoxin targeting HER1. Laprituximab emtansine is an EGFR antibody-drug conjugate (ADC) consisting of the J2898A antibody, DM1 (anti-microtubule agent) and the SMCC thioether linker. Laprituximab emtansine can be used for cancer research[1][2][3]. |
|
| DC65478 |
Cetuximab-MMAE
Featured
|
Cetuximab-MMAE is an antibody-drug conjugate composed of a anti-EGFR monoclonal antibody and a cytotoxic tubulin polymerase inhibitor conjugated through MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) type linker. |
|
| A902 |
Necitumumab (anti-EGFR)
Featured
|
Necitumumab (anti-EGFR) is an epidermal growth factor receptor (EGFR) antagonist that can be used in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer. |
|
| DC65480 |
TPH104m
Featured
|
|
|
| DC65481 |
Eeyarestatin I
Featured
|
Eeyarestatin I is a potent inhibitor of endoplasmic reticulum-associated protein degradation (ERAD). Eeyarestatin I also inhibits Sec61 translocon. |
|
